Trial Profile
A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms ATLANTIC
- Sponsors AstraZeneca
- 23 Oct 2018 Results of a retrospective analysis published in the American Journal of Cardiovascular Drugs
- 25 Sep 2018 Results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 01 Feb 2018 Results evaluating the potential benefit of TA and pre-H ticagrelor treatment in patients enrolled in the ATLANTIC trial published in the American Heart Journal